A small randomized, placebo-controlled clinical trial has found that daily cannabidiol (CBD) was associated with a statistically significant reduction in symptoms among people with obsessive-compulsive disorder, adding new human evidence to the emerging study of cannabinoids and psychiatric conditions.
The research, published in July 2026 in the Annals of Indian Psychiatry, compared daily CBD with placebo in 30 adults diagnosed with obsessive-compulsive disorder (OCD). Participants receiving CBD took 25 milligrams per day as oral drops for eight weeks, while the control group received placebo drops. CBD was used as an adjunctive therapy, meaning participants continued their existing prescribed OCD treatments rather than replacing them with CBD. Investigators measured symptoms using the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), one of the most widely used clinical measures of OCD severity.
The researchers reported that OCD scores declined over the study period in patients receiving CBD and that differences between the CBD and control groups across the measured time points were statistically significant. The findings are noteworthy because controlled clinical evidence involving CBD and OCD remains extremely limited. They do not, however, establish CBD as a proven treatment for OCD. The study included only 30 participants, and the researchers themselves called for larger trials to determine whether the effect can be reproduced.
Researchers Tested CBD for Eight Weeks
The study, titled Evaluation of Cannabidiol Effects as an Adjunctive Therapy on Symptoms of Patients with Obsessive-Compulsive Disorder, was conducted by researchers including Nazli Zahedi, Mahnaz Majidi, Bahare Rezaei, Monirsadat Mirzadeh and Seyed Mohsen Zamir. Participants came from Qazvin Province, Iran.
Thirty patients diagnosed with OCD were randomly assigned to two groups. One received 25 mg of CBD daily, delivered in drops, while the other received placebo drops. Symptoms were assessed at baseline and then again after four and eight weeks using the Y-BOCS. That scale evaluates the severity of obsessions and compulsions by examining factors such as the amount of time symptoms consume, the distress they create, interference with everyday life, resistance to symptoms and a patient’s perceived control over them.
Rather than replacing conventional treatment, CBD was added to participants’ existing care. This is an important distinction when interpreting the findings. The trial therefore provides evidence about CBD as an adjunct, not evidence that CBD can successfully substitute for standard OCD therapy.
Current clinical guidelines continue to identify selective serotonin reuptake inhibitors (SSRIs) and cognitive behavioral therapy—particularly CBT incorporating exposure and response prevention—as first-line treatments for OCD. For people with more severe disease, combinations of medication and CBT are frequently recommended.
OCD Scores Declined in the CBD Group
According to the study abstract, researchers found a decline in mean OCD severity scores over the treatment period among participants receiving CBD. Repeated-measures statistical analysis indicated a significant difference between groups over time, with P < 0.05. The authors concluded that CBD use was associated with a reduction in mean OCD scores and that the difference between the intervention and control groups across the study period was statistically significant.
The publicly accessible abstract does not provide enough detailed numerical information to determine the precise magnitude of the clinical benefit at every assessment point. That matters because statistical significance is not automatically the same thing as a large or clinically meaningful improvement. A larger trial reporting effect sizes, response rates, remission rates and individual Y-BOCS changes would provide a much clearer picture of how substantial the benefit might actually be.
There was also a baseline difference in age between the groups. The mean age was approximately 32.5 years in the CBD group and 40.6 years in the placebo group, a difference the researchers reported as statistically significant. In a study involving only 30 people, baseline imbalances such as this can complicate interpretation and reinforce why replication in a substantially larger randomized population is necessary.
Why Scientists Are Interested in CBD for OCD
OCD is characterized by persistent intrusive thoughts, images or urges—obsessions—and repetitive behaviors or mental rituals known as compulsions. The disorder can substantially interfere with work, relationships and everyday functioning. Although established treatments help many patients, a significant proportion experience residual symptoms or do not respond adequately to initial treatment, creating interest in additional therapeutic targets.
One of those targets is the endocannabinoid system, a signaling network involving endogenous cannabinoids, cannabinoid receptors and enzymes responsible for producing and degrading endocannabinoid molecules. Research increasingly suggests this system interacts with neural pathways involved in anxiety, fear learning, habit formation and repetitive behavior.
A 2024 study published in Translational Psychiatry found selective alterations in endocannabinoid-system gene expression among people with OCD. Researchers reported reduced expression of genes involved in endocannabinoid synthesis, including NAPE-PLD and DAGLα, as well as reduced expression of the CB2 receptor gene in human blood samples. Related changes were also found in brain regions of an animal model displaying compulsive behaviors. The authors argued that the findings strengthen evidence that endocannabinoid signaling may participate in OCD biology.
Those findings do not prove that CBD will treat OCD, but they offer a biological reason to investigate cannabinoids more closely.
Earlier CBD and Cannabis Studies Have Produced Mixed Results
The new trial is especially interesting because earlier controlled research did not clearly demonstrate that CBD reduces OCD symptoms.
In 2020, researchers at Columbia University and the New York State Psychiatric Institute conducted the first placebo-controlled laboratory study examining cannabis in adults with OCD. Fourteen participants entered the trial and 12 completed it. During separate sessions, participants smoked cannabis containing primarily THC, cannabis containing primarily CBD, or placebo cannabis. The CBD-dominant product contained 10.4 percent CBD and 0.4 percent THC.
OCD symptoms declined over time under all three conditions, but neither THC-dominant nor CBD-dominant cannabis produced a significant improvement in OCD symptoms compared with placebo. In fact, state anxiety declined more immediately following placebo than after either active cannabis preparation. Researchers concluded that smoked THC- or CBD-dominant cannabis had little acute impact on OCD symptoms in that experiment.
That study differs considerably from the new Iranian trial. It tested the acute effects of smoked cannabis during laboratory sessions, whereas the 2026 research examined daily oral CBD for eight weeks as an add-on treatment. A therapy could conceivably have little immediate effect yet produce changes after repeated administration, making the different study designs important when comparing results.
Previous Observational Research Has Suggested Possible Benefits
Another 2020 study examined medicinal cannabis use reported by people experiencing OCD symptoms in real-world conditions. Researchers analyzed more than 1,800 cannabis-use sessions recorded by individuals who self-identified as having OCD. Participants generally reported reductions in compulsions, intrusions and anxiety shortly after cannabis use. Higher CBD concentrations were associated with larger reductions in compulsions.
However, that study had major limitations. Participants selected themselves, diagnoses were self-reported, cannabis products were not standardized and there was no placebo group. Researchers also observed evidence that the reduction in intrusive thoughts became smaller with repeated cannabis use, potentially suggesting tolerance.
An open-label CBD study reported in 2023 produced another encouraging signal. Patients with persistent OCD symptoms received 300 mg of CBD per day in addition to conventional treatment, with the dose increased to 600 mg in people who failed to improve sufficiently. Among participants who completed the study, mean Y-BOCS scores reportedly fell from 28.0 at baseline to 13.8 after eight weeks, representing approximately a 51 percent reduction. Because the experiment lacked a placebo control, however, improvement could not confidently be attributed to CBD itself.
The new randomized trial therefore represents a meaningful step forward because it includes a placebo comparison.
The 25 mg Dose Makes This Study Particularly Interesting
One unusual aspect of the new research is the comparatively low CBD dose. Many psychiatric CBD studies have experimented with hundreds of milligrams per day. The earlier open-label OCD research, for example, used 300 to 600 mg daily. The Iranian trial instead administered only 25 mg per day.
That difference makes replication especially important. If a modest daily CBD dose genuinely produces measurable benefits in OCD, it could have important implications for understanding CBD’s dose-response relationship. At the same time, one small study cannot establish that 25 mg represents an effective therapeutic dose. CBD’s pharmacological effects can vary considerably with dosage, formulation, administration route, other medications and individual differences.
Researchers will need larger trials that directly compare multiple doses before determining whether a particular therapeutic range exists for OCD.
A Major 2026 Review Still Finds the Psychiatric Evidence Limited
The positive OCD trial also arrives against a broader scientific backdrop in which evidence supporting cannabinoids for psychiatric disorders remains uncertain.
A systematic review and meta-analysis published in The Lancet Psychiatry in March 2026 examined 54 randomized controlled trials involving 2,477 participants across mental health and substance-use disorders. Nearly half of the included studies were judged to have a high risk of bias, and the certainty of evidence for most outcomes was low. The authors concluded that stronger evidence is needed before cannabinoids can be considered established treatments for most psychiatric conditions.
The review found some evidence of benefits in selected conditions—for example, cannabinoid treatments reduced tic severity in tic disorders or Tourette syndrome and produced some improvements related to cannabis-use disorder—but evidence for many other psychiatric indications remained insufficient. OCD in particular has had so few rigorous trials that researchers still cannot draw strong conclusions.
The newly published CBD study adds an important piece of evidence to that gap, but one trial involving 30 participants is not enough to overturn the larger uncertainty.
CBD Is Not the Same as THC-Rich Marijuana
The findings also should not be interpreted as evidence that smoking marijuana treats OCD. CBD and THC have very different pharmacological profiles. THC is responsible for most of cannabis’s intoxicating effects and can increase anxiety or paranoia in susceptible individuals, particularly at higher doses. CBD is generally non-intoxicating and affects cannabinoid signaling through considerably more complicated mechanisms than simply activating the CB1 receptor.
Research among people with OCD illustrates this distinction. In an Italian study of 70 OCD outpatients, approximately 43 percent reported lifetime cannabis use and 14 percent were current users. Around 10 percent of cannabis users reported that cannabis improved their OCD symptoms, but 23.3 percent reported worsening anxiety.
The results of the CBD trial should therefore be considered evidence about a standardized oral CBD intervention—not a recommendation for self-treatment with high-THC cannabis.
What Researchers Need to Study Next
The next step is straightforward: conduct larger, well-controlled clinical trials involving more diverse populations and longer follow-up periods. Future studies should report detailed Y-BOCS changes, treatment-response and remission rates, adverse effects, medication interactions and whether improvements persist after CBD is discontinued.
Researchers will also need to determine whether certain OCD subgroups respond more strongly than others. OCD is not a single uniform presentation; symptoms can involve contamination fears, checking, symmetry, intrusive thoughts, hoarding-related behaviors and numerous other patterns. Biological differences among patients could potentially influence cannabinoid response.
Mechanistic research may prove equally important. The growing evidence connecting OCD with altered endocannabinoid signaling raises the possibility that CBD affects pathways relevant to obsessive and compulsive behavior, but the precise mechanism remains uncertain. CBD interacts with numerous molecular systems, meaning researchers still need to identify which pathways—if any—are responsible for the clinical signal reported in this trial.
What the New CBD Study Means
The July 2026 study provides one of the clearest controlled signals to date that CBD may have therapeutic potential as an add-on treatment for obsessive-compulsive disorder. Thirty patients were randomized to daily CBD or placebo, symptoms were tracked over eight weeks using the established Y-BOCS scale, and the CBD group showed a statistically significant improvement relative to the control condition over time.
But the most scientifically responsible interpretation is still cautious. The study was small, the groups differed significantly in age at baseline, detailed effect-size information is limited in the publicly accessible report, and previous controlled cannabinoid research in OCD has produced conflicting results. Current evidence therefore supports further investigation, not the conclusion that CBD has been established as an OCD medication.
Still, the trial marks an important development. Evidence connecting the endocannabinoid system with OCD has been accumulating from laboratory studies, case reports, observational research and small clinical experiments. A randomized placebo-controlled trial now adds another piece to that picture. If future studies involving hundreds of patients reproduce the result, CBD could eventually emerge as a novel adjunctive option for a disorder in which many people continue to experience symptoms despite existing treatments.
